Aimmune Therapeutics Inc. (NASDAQ:AIMT) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $38.67 for the company and are anticipating that the company will post ($0.44) earnings per share for the current quarter, according to Zacks. Zacks has also given Aimmune Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.

AIMT has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Wedbush reiterated a “buy” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Wednesday, August 24th. Credit Suisse Group AG reiterated a “buy” rating and issued a $35.00 price objective on shares of Aimmune Therapeutics in a research note on Friday, August 19th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Tuesday, June 14th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/brokerages-expect-aimmune-therapeutics-inc-nasdaqaimt-to-post-0-44-earnings-per-share.html

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.64% during mid-day trading on Tuesday, reaching $15.72. 34,121 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $14.31 and its 200 day moving average price is $13.63. Aimmune Therapeutics has a 52-week low of $9.77 and a 52-week high of $26.50. The company’s market cap is $664.23 million.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.01. On average, equities research analysts predict that Aimmune Therapeutics will post ($1.71) EPS for the current year.

In other Aimmune Therapeutics news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the sale, the insider now owns 30,000 shares in the company, valued at approximately $504,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 24.56% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. raised its stake in shares of Aimmune Therapeutics by 94.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 51,994 shares of the company’s stock worth $563,000 after buying an additional 25,278 shares during the period. American Century Companies Inc. raised its stake in shares of Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock worth $1,063,000 after buying an additional 4,201 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in shares of Aimmune Therapeutics by 116.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 20,796 shares of the company’s stock worth $225,000 after buying an additional 11,179 shares during the period. Highbridge Capital Management LLC acquired a new stake in shares of Aimmune Therapeutics during the second quarter worth approximately $230,000. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Aimmune Therapeutics by 23.4% in the second quarter. Parametric Portfolio Associates LLC now owns 48,270 shares of the company’s stock worth $522,000 after buying an additional 9,156 shares during the period. Institutional investors and hedge funds own 68.87% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.